Case Report

Thymic Hyperplasia after Adjuvant Chemotherapy in Endometrioid Ovarian Cancer-A Rare Case Report

Vakouftsi Alexia-Christina1*, Stamatopoulos Athanasios1, Michos Thrasyvoulos1, Roumpaki Anastasia2, Chatziantoniou Christos1, Kalliopi Diamantopoulou3, Karamanis George1, Liontos Michalis4, Gakidis Ioannis1 and Michos Petros1

1General Thoracic Department, “KAT” Attica General Hospital, Athens, Greece
2General Hospital of Athens “Evangelismos”, Athens, Greece
3Pathology Department, “KAT” Attica General Hospital, Athens, Greece
4Oncology Department, Alexandra General Hospital, Athens, Greece

ARTICLE INFO

Article history:
Received: 29 September, 2020
Accepted: 10 October, 2020
Published: 29 October, 2020

Keywords:
Endometrioid cancer
thymic hyperplasia
adjuvant multidrug chemotherapy
thoracic oncology

ABSTRACT

We present this case to illustrate the fact that doctors need to be cognizant of the unusual presentation of thymic hyperplasia in patients receiving adjuvant chemotherapy for endometrioid ovarian cancer to avoid needless investigations and therapies. Furthermore, this case highlights the need for further studies in order to specify the correlation between thymic hyperplasia and the primary malignancy.

Case History

The patient is a 39-year-old gravida 3 P2102 woman who had undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy for stage IC2 (T1C2-N0-M0) according to FIGO and TNM staging systems endometrioid ovarian cancer in June of 2018. The tumor was ER(+), WT1(+), P16 and P53(-). In August of 2018, 6 cycles of adjuvant chemotherapy with Adriamycin and cisplatin was begun, completed in February of 2019. Thereafter, the patient reached complete remission and was referred to follow-up. 8 months later a CT chest scan revealed a 6 cm mass in the anterior mediastinum. The patient meanwhile was in excellent condition, tumor markers were within normal limits and no other signs of relapse were evident. Consequently, the patient was referred to our department for consultation and further evaluation.

Investigations

Baseline CT scan (post adjuvant chemotherapy): 1.5 cm anterior mediastinal mass; CT scan: 6 cm anterior mediastinal mass (Figures 1 &
Thymic Hyperplasia after Adjuvant Chemotherapy in Endometrioid Ovarian Cancer—A Rare Case Report

2); PET scan: Showed no uptake in the thymus; CBC with differential showed no abnormalities or atypical lymphocytosis prior to and after the development of thymic mass; Physical examination: No clinical signs or symptoms of myasthenia Gravis.

Results and Treatment

After joined consultation with her oncologist a surgical approach was chosen. In November of 2019 a median sternotomy was performed with a radical thymectomy. Intraoperatively, it had been identified as an enlarged thymus (9.5 x 6 x 2.3 cm, 47 gr weight) (Figure 3).

Histopathology Results

Histologic examination of the thymus revealed a normal lobular architecture with a distinct corticomedullary demarcation and numerous Hassall’s corpuscles (Figure 4). Only few adipocytes were distributed throughout the thymic tissue (Figure 5). Formaldehyde-fixed and paraffin-embedded material as well as shock-frozen sections were available and after immunohistochemical test with CKAE1/AE3, CK18, CK19, CK20, CK7, CK10, CK14, CK8, CD10, CD79a, CD20, CD19, CD3, CD4, CD8, CD40, P53 and Ki67 the specimen was identified as thymic hyperplasia.

Discussion

True thymic hyperplasia such as occurred in this case is rare in adults. It is defined pathologically as an increase in both size and weight of the gland, with retention of normal microscopic architecture. Thymic hyperplasia is a very rare pathology that presents radiologically as mediastinal mass. Presumably, thymic hyperplasia after chemotherapy is more common in younger populations because the proportion of such patients with significant amounts of residual thymic tissue is greater. Thymic hyperplasia is neither tumor nor treatment specific. In some cases, it is not possible to make the distinction between a mediastinal mass due to thymic enlargement and recurrent or residual malignancy on clinical and CT scan criteria alone. Where significant doubt exists, mediastinal exploration and histological assessment may be necessary [1]. Pathophysiology of rebound thymic hyperplasia constitutes a controversial topic and it is outmost significance to distinguish it from recurrent or residual malignant disease.

Conventionally, atrophy is the first step elicited by steroid related apoptosis and inhibition of lymphocyte proliferation which is observed not only after chemotherapy but for instance in acute infection, stress, or radiation. In the sense of an immunologic rebound phenomenon, lymph follicles with large nuclear center and infiltration with plasma cells develop after the chemotherapy [2]. In these patients, hyperplasia may reflect an active cellular immune response to tumor, with an increase in naïve T cell production and facilitate an important prognostic indicator of hosts immunologic response [3–6]. Other investigators have suggested that thymic hyperplasia is caused by chemotherapy-induced gonadal atrophy, which results in increase LH hormone secretion [7–8].

Conclusion

The case presented here illustrates the fact that doctors need to be cognizant of the unusual presentation of thymic hyperplasia in patients receiving adjuvant chemotherapy for endometrioid ovarian cancer. PET scan was helpful modality in distinguishing a benign from a malignant process. The patient is in clinical remission. Thymic hyperplasia may indicate an active cellular immune response against a tumor, thereby serving as a favorable prognostic marker. Getting acquainted with this unusual side effect may prevent needless investigation and therapy. In conclusion, the pathophysiology and clinical significance of thymic rebound phenomena in endometrioid ovarian cancer patients requires further studies.
REFERENCES


4. Mackall CL, Fleisher TA, Brown MA, Andrich MP, Chen CC et al. (1997) Distinctions between CD8+ and CD4+ T cell regenerative pathways result in prolonged T cell subset imbalance after invasive chemotherapy. Blood 89: 3700-3707. [Crossref]

5. Mackall CL, Hakim FT, Gress RE (1997) T cell regeneration: all repertoires are not created equal. Immunol Today 18: 245-251. [Crossref]

